PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES

• Mitsuhito Hirano,
• Kikuaki Yoshida,
• Kei Hirano,
• Yukako Teramoto,
• Mikako Tamba,
• Nobuhiko Yamauchi,
• Yuko Shirouchi,
• Yuko Ishihara,
• Hiroaki Asai,
• Yuko Mishima,
• Kengo Takeuchi,
• Dai Maruyama

Affiliations

Mitsuhito Hirano

1 Japanese Foundation for Cancer Research, Department of Hematology Oncology, Koto City, Japan

Kikuaki Yoshida

1 Japanese Foundation for Cancer Research, Department of Hematology Oncology, Koto City, Japan

Kei Hirano

1 Japanese Foundation for Cancer Research, Department of Hematology Oncology, Koto City, Japan

Yukako Teramoto

1 Japanese Foundation for Cancer Research, Department of Hematology Oncology, Koto City, Japan

Mikako Tamba

1 Japanese Foundation for Cancer Research, Department of Hematology Oncology, Koto City, Japan

Nobuhiko Yamauchi

1 Japanese Foundation for Cancer Research, Department of Hematology Oncology, Koto City, Japan

Yuko Shirouchi

1 Japanese Foundation for Cancer Research, Department of Hematology Oncology, Koto City, Japan

Yuko Ishihara

1 Japanese Foundation for Cancer Research, Department of Hematology Oncology, Koto City, Japan

Hiroaki Asai

1 Japanese Foundation for Cancer Research, Department of Hematology Oncology, Koto City, Japan

Yuko Mishima

1 Japanese Foundation for Cancer Research, Department of Hematology Oncology, Koto City, Japan

Kengo Takeuchi

2 Japanese Foundation for Cancer Research, Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Koto City, Japan

Dai Maruyama

1 Japanese Foundation for Cancer Research, Department of Hematology Oncology, Koto City, Japan